US 12,109,203 B2
Substituted oxazolidinones for the treatment of mammalian infections
Ranjit Desai, Gujarat (IN); Vrajesh Pandya, Gujarat (IN); Mehul Pujara, Gujarat (IN); Anil Argade, Gujarat (IN); Jignesh Joshi, Gujarat (IN); and Anshul Satyanand, Gujarat (IN)
Assigned to ZYDUS LIFESCIENCES LIMITED, Gujarat (IN)
Appl. No. 17/262,278
Filed by CADILA HEALTHCARE LIMITED, Gujarat (IN)
PCT Filed Jul. 24, 2019, PCT No. PCT/IB2019/056322
§ 371(c)(1), (2) Date Jan. 22, 2021,
PCT Pub. No. WO2020/021468, PCT Pub. Date Jan. 30, 2020.
Claims priority of application No. 201821027940 (IN), filed on Jul. 25, 2018.
Prior Publication US 2021/0267953 A1, Sep. 2, 2021
Int. Cl. A61K 31/438 (2006.01); A61K 31/133 (2006.01); A61K 31/4409 (2006.01); A61K 31/454 (2006.01); A61K 31/496 (2006.01); A61K 31/4965 (2006.01); A61K 31/5383 (2006.01); A61K 31/606 (2006.01); A61K 31/7036 (2006.01); A61P 31/04 (2006.01); C07D 413/14 (2006.01); C07D 491/107 (2006.01); C07D 495/10 (2006.01)
CPC A61K 31/438 (2013.01) [A61K 31/133 (2013.01); A61K 31/4409 (2013.01); A61K 31/454 (2013.01); A61K 31/496 (2013.01); A61K 31/4965 (2013.01); A61K 31/5383 (2013.01); A61K 31/606 (2013.01); A61K 31/7036 (2013.01); A61P 31/04 (2018.01); C07D 413/14 (2013.01); C07D 491/107 (2013.01); C07D 495/10 (2013.01)] 6 Claims
 
1. A compound of general formula (I),

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein, X is either absent or a bond;
whenever X is absent, the four membered ring is directly attached to the 6-membered piperidine ring forming spirocyclic system with the spiro carbon at position 4 of the piperidine ring and Q being beta to the spiro carbon; Q is either O or S(O)p; p=0-2 integer; Y is OH, NR2R3, or NHC(O)R4; R1 is selected from H, F, Cl, CH3, CN and OCH3; m=1-4 integer; R2 and R3 are independently selected from H, (C1-C6)alkyl, (C3-C6)cycloalkyl, aryl, heterocyclyl and heteroaryl each of which may be further optionally substituted; or Rz and R3 are taken together with the nitrogen to which they are attached to form a 4- to 8-membered heterocyclyl or heteroaryl with 1 to 3 additional heteroatoms selected from O, S, or N, which heterocyclyl or heteroaryl may be further be optionally substituted; R4 is independently selected from (C1-C6)alkyl, (C3-C6)cycloalkyl, aryl, heteroaryl and (C1-C6)alkoxy, each of which is optionally substituted; substitutions are selected from halo, hydroxyl, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)acyloxy, haloalkyl, NO2, CN and NH2.